Rapid Payer Coverage And International Expansion Are Expected To Drive Long-Term Upside

Catalysts

About Soleno Therapeutics

Soleno Therapeutics develops and commercializes therapies for Prader-Willi syndrome, focusing on hyperphagia and its life-threatening complications.

What are the underlying business or industry changes driving this perspective?

• Rapid uptake of VYKAT XR as the first and only FDA approved treatment for PWS related hyperphagia, with more than 1,000 patient start forms and 764 active patients within six months, supports a path to sustained revenue growth as penetration into an estimated 10,000 patient U.S. market increases.
• Expanding prescriber base, including nearly 500 unique prescribers and growing adoption beyond KOL centers into community practices, should drive broader utilization over time and improve top line visibility as clinics formalize dedicated PWS programs.
• Strengthening payer coverage across commercial, Medicaid and Medicare, with policies now covering roughly 132 million lives and broad state Medicaid reimbursement, reduces access friction and is likely to support higher realized revenue and more predictable cash flows.
• Progress toward EMA approval of DCCR in Europe, where approximately 9,500 additional PWS patients are concentrated in major markets with high diagnostic rates, offers a clear international expansion opportunity that can materially increase total revenue and improve earnings leverage on a largely fixed U.S. cost base.
• Strong balance sheet with over $550 million in cash and consistent operating cash generation enables continued investment in commercial infrastructure, education and data generation, which can enhance VYKAT XR’s standard of care positioning and support durable net margin improvement as scale increases.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Soleno Therapeutics's revenue will grow by 115.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from -79.5% today to 57.8% in 3 years time.
• Analysts expect earnings to reach $567.7 million (and earnings per share of $9.85) by about December 2028, up from $-78.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.0 billion in earnings, and the most bearish expecting $444.5 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.1x on those 2028 earnings, up from -34.7x today. This future PE is lower than the current PE for the US Biotechs industry at 19.6x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.04%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Launch momentum could slow structurally rather than temporarily if the combination of summer seasonality, holiday related complexities for hyperphagia, and lingering effects from the short seller report keep patient start forms and prescriber enthusiasm below expectations over multiple quarters. This would directly constrain revenue growth and future earnings power.
• Safety perceptions may deteriorate if fluid retention and hyperglycemia events, even when medically nonserious and on label, continue to drive higher than anticipated early discontinuations among less experienced community prescribers and anxious caregivers. This would cap long term patient persistence and reduce net revenue and operating margins.
• Dependence on a concentrated rare disease market means that if the estimated 10,000 to 12,000 U.S. Prader Willi patients are not fully captured because some remain undiagnosed, are managed in fragmented care settings, or opt out of therapy despite education efforts, the long term addressable market could prove smaller than forecast. That would limit top line expansion and scale driven margin improvement.
• International growth may underwhelm if European regulators raise additional efficacy or trial design concerns during the EMA review, extend timelines, or ultimately restrict the label. This would delay or reduce expected EU adoption and thereby dampen the contribution of ex U.S. sales to consolidated revenue and earnings growth.
• Emerging competition and evolving standards of care in obesity and metabolic disease, including Rhythm Pharmaceuticals exploration of setmelanotide in Prader Willi and broader GLP 1 or combination approaches, could shift prescriber preference or lead to combination regimens that dilute VYKAT XR utilization. That would place long term pressure on pricing, net revenue per patient, and sustainable net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $113.54 for Soleno Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $145.0, and the most bearish reporting a price target of just $75.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be $982.8 million, earnings will come to $567.7 million, and it would be trading on a PE ratio of 16.1x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $50.72, the analyst price target of $113.54 is 55.3% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.